Three Firms Aid SPAC Tie-up for Cardio-Focused Biopharma Company

Covington & Burling is representing NewAmsterdam Pharma Holding B.V., a Netherlands-based clinical-stage biopharmaceutical company focused on oral therapies for cardio-metabolic diseases, on its go-public merger with a special purpose acquisition company.

Goodwin Procter is counseling the SPAC, Frazier Lifesciences Acquisition Corporation, which is sponsored by an affiliate of Seattle-based private equity firm Frazier Healthcare Partners, according to a statement.

NewAmsterdam Pharma says its lead therapeutic candidate, obicetrapib, could potentially serve 30 million patients worldwide who have cardiovascular disease.

After the merger’s expected second-half closing, the new holding company NewAmsterdam Pharma Company N.V., is expected to be listed on the Nasdaq ...